Undisclosed Multispecific Therapeutics
Immuno-Oncology
Key Facts
About ModeX Therapeutics
ModeX Therapeutics is a private, preclinical-stage biotech focused on creating multispecific biologic drugs using its proprietary MSTAR and Nanoparticle Vaccine platforms. The company, a spin-out/affiliate of OPKO Health, is led by a highly experienced team with deep roots in academia, government (NIH), and industry. Its strategy centers on developing single-molecule therapies that engage multiple disease targets simultaneously, aiming to improve efficacy and overcome limitations of traditional monoclonal antibodies in complex diseases like oncology and virology.
View full company profileAbout ModeX Therapeutics
ModeX Therapeutics is a private, preclinical-stage biotech focused on creating multispecific biologic drugs using its proprietary MSTAR and Nanoparticle Vaccine platforms. The company, a spin-out/affiliate of OPKO Health, is led by a highly experienced team with deep roots in academia, government (NIH), and industry. Its strategy centers on developing single-molecule therapies that engage multiple disease targets simultaneously, aiming to improve efficacy and overcome limitations of traditional monoclonal antibodies in complex diseases like oncology and virology.
View full company profileTherapeutic Areas
Other Immuno-Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| PD-1/PD-L1 Inhibitor Binding Assay Kit | Aurora Biolabs | Commercial |
| CTLA-4/B7-1 Inhibitor Screening Kit | Aurora Biolabs | Commercial |
| OX40 & PD-1 Assay | Aurora Biolabs | Commercial |
| HPK1 inhibitor | Acellera | Pre-clinical |
| SKP2-CKS1 PPI Inhibitor | Iktos | Hit-to-Lead |
| PD-1 Expression Inhibitor | BCN Biosciences | Preclinical |
| CCR8 ADC | Integral Molecular | Preclinical |
| KB16A | KBio | Discovery |
| NeoSight Neoantigen Detection | ReproCELL | Research/Clinical |
| EMUNKITUG (HFB200301) | HiFiBiO Therapeutics | Phase 1 |
| HFB200603 | HiFiBiO Therapeutics | Phase 1 |
| Undisclosed | Onco3R Therapeutics | Preclinical |